RIOX1

RIOX1 (NO66) is a nucleolar and nucleoplasmic JmjC-domain 2-oxoglutarate oxygenase that integrates chromatin regulation, ribosome biogenesis, and DNA repair through distinct catalytic activities (PMID:14742713, PMID:19927124). As a histone demethylase, it removes H3K4me and H3K36me marks to repress transcription, and this catalytic activity is required to silence osteoblast-specific promoters where it binds and antagonizes the transcription factor Osterix (PMID:19927124, PMID:25736226). Its chromatin function is directed by partner-based recruitment: PHF19 delivers both RIOX1 and the PRC2 complex to stem cell genes during differentiation, coupling RIOX1-catalyzed H3K36me3 demethylation to PRC2-mediated H3K27me3 deposition and transcriptional silencing (PMID:23160351), while a repressor complex with DNMT1, HDAC1, and HP1 — with HP1 stimulating RIOX1 demethylase activity — reinforces gene repression (PMID:24115157). Structurally, RIOX1 assembles into a functional tetramer via a hinge domain that links its JmjC and winged helix-turn-helix domains, and this oligomerization interface both engages Osterix and is required for catalytic efficiency (PMID:23620590, PMID:26327385). Beyond histones, RIOX1 acts as a ribosomal protein hydroxylase, catalyzing C-3 histidine hydroxylation of Rpl8 through recognition of an NHXH consensus motif (PMID:26327385), and as a protein demethylase that removes monomethylation at cGAS K491, releasing cGAS from the reader SGF29 so that it impedes PARP1-dependent homologous recombination repair (PMID:35210392). In vivo, RIOX1 demethylase activity negatively regulates bone formation (PMID:25736226), and its catalytic function suppresses proliferation and rDNA transcription while promoting myeloid commitment in leukemic cells (PMID:33745927).

1. 2004 Medium

   Established where NO66 acts in the cell, placing an uncharacterized protein at the interface of ribosome biogenesis and heterochromatin before any enzymatic activity was known.

   Evidence Immunolocalization with Ki-67/HP1α/PCNA, biochemical fractionation, and mass spectrometry of Xenopus nucleoli

   PMID:14742713

   Open questions at the time

   • No catalytic activity or substrate identified
   • Functional role in ribosome biogenesis vs. heterochromatin not dissected
2. 2009 High

   Defined NO66 as a JmjC histone demethylase whose H3K4me/H3K36me activity represses transcription, linking it mechanistically to Osterix-controlled osteoblast gene programs.

   Evidence Co-IP of Osx interactors, in vitro demethylase assays, ChIP, and NO66 knockdown with differentiation readouts

   PMID:19927124

   Open questions at the time

   • Recruitment mechanism to target loci unresolved
   • Structural basis of demethylation not defined
3. 2012 High

   Showed how NO66 is targeted to chromatin, revealing PHF19/PRC2-dependent recruitment that couples its H3K36me3 demethylation to Polycomb silencing during differentiation.

   Evidence Co-IP, ChIP for multiple histone marks, and PHF19 knockdown in mouse embryonic stem cells

   PMID:23160351

   Open questions at the time

   • Direct vs. indirect PHF19-NO66 contact not mapped
   • Generality beyond stem cell genes untested
4. 2013 High

   Resolved the architecture of NO66, establishing that hinge-dependent tetramerization is required both for catalysis and for binding Osterix.

   Evidence X-ray crystallography with mutagenesis of the oligomerization interface and promoter reporter assays

   PMID:23620590

   Open questions at the time

   • Oligomeric state in vivo not directly demonstrated
   • Structure of the JmjC-substrate complex not yet captured
5. 2014 Medium

   Expanded the repressive machinery around NO66, identifying a DNMT1/HDAC1/HP1 corepressor complex in which HP1 stimulates demethylase activity.

   Evidence ChIP in Osx-null cells, Co-IP of NO66 partners, and in vitro demethylase assays with HP1

   PMID:24115157

   Open questions at the time

   • Single-lab data without reciprocal validation of all interactions
   • Mechanism of HP1 stimulation unresolved
6. 2015 High

   Identified a second catalytic activity, defining NO66 as an Rpl8 histidine C-3 hydroxylase that recognizes an NHXH motif and requires oligomerization for efficiency.

   Evidence Crystal structure of NO66-Rpl8 peptide complex, in vitro hydroxylase assays, and oligomeric mutant analysis

   PMID:26327385

   Open questions at the time

   • Functional consequence of Rpl8 hydroxylation for ribosome function untested
   • Full substrate repertoire of the NHXH motif unknown
7. 2015 High

   Provided in vivo loss-of-function proof that NO66 demethylase activity restrains osteogenesis, validating the chromatin-repressor model at the organismal level.

   Evidence Mesenchymal-specific conditional knockout mice (Prx1-Cre), histomorphometry, and bone marker expression analysis

   PMID:25736226

   Open questions at the time

   • Did not separate histone demethylase from hydroxylase contributions in vivo
   • Cell-autonomy of the phenotype not fully resolved
8. 2018 Medium

   Mapped the determinant of nucleolar targeting to a unique N-terminal extension and established the intronless single-exon gene structure across metazoans.

   Evidence Immunofluorescence with domain mapping in HeLa cells and comparative genomics across 49 species

   PMID:29914368

   Open questions at the time

   • Functional consequence of nucleolar targeting not tested
   • No link to catalytic activities
9. 2021 Medium

   Demonstrated catalytic dependence of NO66's tumor-suppressive role in AML, showing it inhibits proliferation and rDNA transcription and drives myeloid commitment, with promoter hypermethylation silencing it in leukemic cells.

   Evidence Wild-type vs. catalytic-dead NO66 stable expression in KG1a cells, rDNA transcription and proliferation assays, bisulfite sequencing, expression profiling

   PMID:33745927

   Open questions at the time

   • Direct substrate driving the AML phenotype not identified
   • Single cell-line system
10. 2022 High

    Extended NO66 substrate specificity beyond histones, showing it demethylates cGAS K491 to control homologous recombination by gating cGAS-PARP1 interaction at DNA breaks.

    Evidence RIOX1 depletion, in vitro demethylation on cGAS K491, reciprocal Co-IPs (cGAS-SGF29, cGAS-PARP1), and HR/NHEJ reporter assays under irradiation

    PMID:35210392

    Open questions at the time

    • Whether cGAS demethylation occurs at chromatin loci shared with histone substrates unknown
    • Relative contribution to repair vs. innate immune cGAS signaling unresolved
11. 2023 Medium

    Characterized the narrow substrate selectivity of NO66 histidine hydroxylation and showed histidine analogues can inhibit activity, raising the possibility of endogenous competitive regulation.

    Evidence In vitro hydroxylation and inhibition assays with natural and unnatural histidine analogues in Rpl peptides

    PMID:36908702

    Open questions at the time

    • In vivo competitive inhibition mechanism not validated
    • Physiological inhibitor not identified

• How the distinct catalytic activities of RIOX1 — histone demethylation, ribosomal protein hydroxylation, and cGAS demethylation — are coordinated within a single protein and partitioned between nucleolar and chromatin compartments remains unresolved.
• No unified model integrating the three activities
• Compartment-specific substrate engagement not mapped
• Regulation switching between functions unknown